Marin-Acevedo, J. A. et al. Next generation of immune checkpoint therapy in cancer: New developments and challenges. J. Hematol. Oncol. 11, 1–20 (2018).
Hahn, A. W., Gill, D. M., Pal, S. K. & Agarwal, N. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. Immunotherapy 9, 681–692 (2017).
Google Scholar
Weber, J. Immune checkpoint proteins: A new therapeutic paradigm for cancerpreclinical background: CTLA-4 and PD-1 blockade. Semin. Oncol. 37, 430–439 (2010).
Google Scholar
Collin, M. Immune checkpoint inhibitors: A patent review (2010–2015). Expert Opin. Ther. Pat. 26, 555–564 (2016).
Google Scholar
Hargadon, K. M., Johnson, C. E. & Williams, C. J. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Int. Immunopharmacol. 62, 29–39 (2018).
Google Scholar
Darvin, P., Toor, S. M., Sasidharan Nair, V. & Elkord, E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp. Mol. Med. 50, 1–11 (2018).
Google Scholar
Carosella, E. D., Ploussard, G., LeMaoult, J. & Desgrandchamps, F. A systematic review of immunotherapy in urologic cancer: Evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur. Urol. 68, 267–279 (2015).
Google Scholar
Carosella, E. D., Rouas-Freiss, N., Roux, D. T. Le, Moreau, P. & LeMaoult, J. HLA-G. An Immune Checkpoint Molecule. Advances in Immunology vol. 127 (Elsevier Inc., 2015).
Rouas-Freiss, N., Gonçalves, R. M. B., Menier, C., Dausset, J. & Carosella, E. D. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc. Natl. Acad. Sci. USA 94, 11520–11525 (1997).
Google Scholar
Riteau, B. et al. HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J. Immunol. 166, 5018–5026 (2001).
Google Scholar
Tronik-Le Roux, D. et al. Novel landscape of HLA-G isoforms expressed in clear cell renal cell carcinoma patients. Mol. Oncol. 11, 1561–1578 (2017).
LeMaoult, J., Krawice-Radanne, I., Dausset, J. & Carosella, E. D. HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells. Proc. Natl. Acad. Sci. USA 101, 7064–7069 (2004).
Google Scholar
Lefebvre, S. et al. Modulation of HLA-G expression in human thymic and amniotic epithelial cells. Hum. Immunol. 61, 1095–1101 (2000).
Google Scholar
Le Discorde, M., Moreau, P., Sabatier, P., Legeais, J. M. & Carosella, E. D. Expression of HLA-G in human cornea, an immune-privileged tissue. In Human Immunology vol. 64 1039–1044 (Elsevier Inc., 2003).
Menier, C. et al. Erythroblasts secrete the nonclassical HLA-G molecule from primitive to definitive hematopoiesis. Blood 104, 3153–3160 (2004).
Google Scholar
Loumagne, L. et al. In vivo evidence that secretion of HLA-G by immunogenic tumor cells allows their evasion from immunosurveillance. Int. J. Cancer 135, 2107–2117 (2014).
Google Scholar
Sasidharan Nair, V. & Elkord, E. Immune checkpoint inhibitors in cancer therapy: A focus on T-regulatory cells: A. Immunol. Cell Biol. 96, 21–33 (2018).
Google Scholar
Huang, C. H., Lee, K. C. & Doudna, J. A. Applications of CRISPR-Cas enzymes in cancer therapeutics and detection. Trends Cancer 4, 499–512 (2018).
Google Scholar
Liu, B., Saber, A. & Haisma, H. J. CRISPR/Cas9: A powerful tool for identification of new targets for cancer treatment. Drug Discov. Today 24, 955–970 (2019).
Google Scholar
Zhang, C., Peng, Y., Hublitz, P., Zhang, H. & Dong, T. Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy. Sci. Rep. 8, 1–13 (2018).
Google Scholar
Van Acker, H. H., Capsomidis, A., Smits, E. L. & Van Tendeloo, V. F. CD56 in the immune system: More than a marker for cytotoxicity?. Front. Immunol. 8, 1–9 (2017).
Dumont, C. et al. CD8+PD-1– ILT2+ T cells are an intratumoral cytotoxic population selectively inhibited by the immune-checkpoint HLA-G. Cancer Immunol. Res. 7, 1619–1632 (2019).
Google Scholar
George, S., Rini, B. I. & Hammers, H. J. Emerging role of combination immunotherapy in the first-line treatment of advanced renal cell carcinoma: A review. JAMA Oncol. 5, 411–421 (2019).
Google Scholar
Jain, P., Jain, C. & Velcheti, V. Role of immune-checkpoint inhibitors in lung cancer. Ther. Adv. Respir. Dis. 12, 1–13 (2018).
Google Scholar
Lalani, A. K. A. et al. Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: Current paradigms, use of immunotherapy, and future directions. Eur. Urol. 75, 100–110 (2019).
Google Scholar
Lazarus, G., Audrey, J. & Iskandar, A. W. B. Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review. Oncol. Rev. 13, 161–169 (2019).
Lugowska, I., Teterycz, P. & Rutkowski, P. Immunotherapy of Melanoma. Contemp. Oncol. 22, 61–67 (2018).
Rotte, A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J. Exp. Clin. Cancer Res. 38, 1–12 (2019).
Cooper, M. R., Alrajhi, A. M. & Durand, C. R. Role of immune checkpoint inhibitors in small cell lung cancer. Am. J. Ther. 25, e349–e356 (2018).
Google Scholar
Lin, A. & Yan, W. H. Heterogeneity of HLA-G expression in cancers: Facing the challenges. Front. Immunol. 9, 2164 (2018).
Google Scholar
Menier, C., Rouas-Freiss, N. & Carosella, E. The HLA-G non classical MHC class I molecule is expressed in cancer with poor prognosis. Implications in tumour escape from immune system and clinical applications. Atlas Genet. Cytogenet. Oncol. Haematol. 13, 531–542 (2011).
Kochetov, A. V. Alternative translation start sites and hidden coding potential of eukaryotic mRNAs. BioEssays 30, 683–691 (2008).
Google Scholar
Brogna, S. & Wen, J. Nonsense-mediated mRNA decay (NMD) mechanisms. Nat. Struct. Mol. Biol. 16, 107–113 (2009).
Google Scholar
Hug, N., Longman, D. & Cáceres, J. F. Mechanism and regulation of the nonsense-mediated decay pathway. Nucleic Acids Res. 44, 1483–1495 (2015).
Butler, J. E. F. & Kadonaga, J. T. The RNA polymerase II core promoter: A key component in the regulation of gene expression. Genes Dev. 16, 2583–2592 (2002).
Google Scholar
Wan, T. et al. Genome editing of mutant KRAS through supramolecular polymer-mediated delivery of Cas9 ribonucleoprotein for colorectal cancer therapy. J. Control. Release 322, 236–247 (2020).
Google Scholar
Baliou, S. et al. CRISPR therapeutic tools for complex genetic disorders and cancer (Review). Int. J. Oncol. 53, 443–468 (2018).
Google Scholar
Mollanoori, H., Shahraki, H., Rahmati, Y. & Teimourian, S. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment. Hum. Immunol. 79, 876–882 (2018).
Google Scholar
Hu, W. et al. CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions. Cancer Immunol. Immunother. 68, 365–377 (2019).
Google Scholar
Wu, S. S., Li, Q. C., Yin, C. Q., Xue, W. & Song, C. Q. Advances in CRISPR/Cas-based gene therapy in human genetic diseases. Theranostics 10, 4374–4382 (2020).
Google Scholar
Hung, S. S. C. et al. AAV-Mediated CRISPR/Cas gene editing of retinal cells in vivo. Investig. Ophthalmol. Vis. Sci. 57, 3470–3476 (2016).
Google Scholar
Chew, W. L. et al. A multifunctional AAV-CRISPR-Cas9 and its host response. Nat. Methods 13, 868–874 (2016).
Google Scholar
Wang, D., Zhang, F. & Gao, G. CRISPR-based therapeutic genome editing: Strategies and in vivo delivery by AAV vectors. Cell 181, 136–150 (2020).
Google Scholar
Wittnebel, S. et al. The sensitivity of renal cell carcinoma cells to interferon alpha correlates with p53-induction and involves Bax. Eur. Cytokine Netw. 16, 123–127 (2005).
Google Scholar
García, M. et al. The immune-checkpoint HLA-G/ILT4 is involved in the regulation of VEGF expression in clear cell renal cell carcinoma. BMC Cancer https://doi.org/10.1186/s12885-020-07113-8 (2020).
Google Scholar
Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308 (2013).
Google Scholar
Moro, L. N. et al. Generation of myostatin edited horse embryos using CRISPR/Cas9 technology and somatic cell nuclear transfer. Sci. Rep. 10, 1–10 (2020).
Google Scholar
Zilberman, S. et al. HLA-G1 and HLA-G5 active dimers are present in malignant cells and effusions: The influence of the tumor microenvironment. Eur. J. Immunol. 42, 1599–1608 (2012).
Google Scholar
Hsiau, T. et al. Inference of CRISPR Edits from Sanger Trace Data. bioRxiv 1–17. https://doi.org/10.1101/251082 (2019).
Luzzani, C. et al. A therapy-grade protocol for differentiation of pluripotent stem cells into mesenchymal stem cells using platelet lysate as supplement. Stem Cell Res. Ther. 6, 1–13 (2015).
